Search results
Genentech’s Phase III STARGLO Study Demonstrates Columvi Significantly Extends Survival in People...
Morningstar· 7 days agoGenentech’s Phase III STARGLO Study Demonstrates Columvi Significantly Extends Survival in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma – The study met ...
The Swiftly Evolving Story of EGFR-Mutated NSCLC Management
MedPage Today· 16 hours agoFor patients with non-small lung cancer (NSCLC), the ADAURA, FLAURA and MARIPOSA trials bestowed...
Sanofi heads out to surf Belharra in $700M biobucks immunology deal
FierceBiotech· 4 days agoSanofi is offering Belharra Therapeutics up to $700 million in biobucks for a tow out to surf the...
Glofitamab Regimen Improves Survival in DLBCL
MedPage Today· 2 days agoGranted accelerated approval last year, bispecific antibody passes its confirmatory test
Beyond BCMA-Directed CAR T-Cell Therapy
MedPage Today· 1 day agoAlthough survival rates for patients with multiple myeloma are improving, with a 5-year rate of about 60%, many patients relapse after treatment. "Patients have seen impressive advances in survival ...
Rethinking Clinical Trial Design and Cure in NSCLC
Medscape· 2 days agoMark Kris discusses clinical trial design and the goal of cure in non–small cell lung cancer.
Pharma giant's data breach exposes patients' sensitive information
Fox News· 5 days agoU.S. pharmaceutical giant Cencora has been affected by a data breach. The company is notifying...
EHA 2024: Odronextamab shows promise in ELM-2 study for follicular lymphoma
Clinical Trials Arena via Yahoo Finance· 5 days agoHowever, Odronextamab, if approved, will face fierce competition with two other BiTEs, AbbVie and...
Sanofi and Belharra forge $700m partnership for immunological diseases
Pharmaceutical Technology via Yahoo Finance· 4 days agoIn January 2023, Belharra signed a multi-year partnership with Roche Group member Genentech to...
Three-Drug Regimens Make Case for a Role in Untreated and Relapsed/Refractory CLL
MedPage Today· 5 days agoA fixed-duration, three-drug regimen for chronic lymphocytic leukemia (CLL) achieved deep and...